The Ebola Outbreak In Uganda: Kenya Following Will Check Tourists At Border Crossings

Following an Ebola epidemic in the neighboring country of Uganda, Kenya will start inspecting tourists and truck drivers at all county boundary crossings.

WHO Confirmation

A 24-year-old man from Uganda’s central Mubende area died yesterday, according to the World Health Organization (WHO). He exhibited Ebola symptoms, including high fever, diarrhea, bloody vomiting, and abdominal pain.

Since then, the Kenyan Ministry of Health has issued a warning, urging residents to exercise caution and step-up security at all national borders.

Health Cabinet Secretary Mutahi Kagwe has requested that the countries bordering Uganda take safeguards, including checking visitors and truck drivers, in a circular dated Wednesday, September 21. Kagwe claims that the alert aligns with East African Community (EAC) health procedures.

Road, air, and sea travel are the primary modes of transportation (through Lake Victoria). Border crossing locations like Busia, Malaba, Lwakhakha, and Suam are among the formal and informal land crossings. All of these increase Kenya’s vulnerability to disease importation; as a result, the public must exercise caution and report any suspected instances, Kagwe admonished.

Simulatneously, he urged travelers to the Democratic Republic of the Congo and Uganda to exercise extra vigilance.

The CS also urged people to keep an eye out for anyone exhibiting an acute start of fever, mainly if they have recently come into contact with anyone who has travelled to Uganda or DR Congo.

Ebola Virus

The Ebola virus (EVD) is a rare and fatal condition affecting humans and nonhuman primates. People who come into contact with an infected bat or nonhuman primate or a sick or deceased Ebola virus-infected person directly may get EVD.

The Ebola virus was initially found in 1976 in the area of what is now the Democratic Republic of the Congo, close to the Ebola River. Since then, sporadic cases of the virus have caused outbreaks in several African nations. Where the Ebola virus originates is unknown to scientists. They contend that EVD is animal-borne and that nonhuman primates or bats are the most credible sources, based on the similarity of the viruses involved. Apes, monkeys, duikers, and humans are among the species that can contract the virus from infected animals carrying it.

The virus first infects humans through direct contact with the blood, bodily fluids, and tissues of animals. Then, the Ebola virus spreads to new victims when they come into contact with the bodily fluids of an EVD patient or victim. This can happen if someone comes in contact with particular contaminated objects or body fluids. The virus then enters the body via rashes or damaged mucous membranes in the mouth, nose, or eyes. The virus can be acquired through sexual contact with a person who has EVD or has recovered from it. After the disease has passed, the virus may still be present in some bodily fluids, such as semen.


After they have recovered, Ebola survivors could endure side effects. These might include stomach pain, eye and vision issues, fatigue, and muscle aches.


On December 19, 2019, the American Food and Drug Administration (FDA) authorized the rVSV-ZEBOV Ebola vaccine, also known as Ervebo®. This is the first Ebola vaccine that the FDA has approved.

The Zaire ebolavirus, which has been responsible for the biggest and deadliest Ebola outbreaks to date, has been proven safe and resistant to this vaccine, administered as a single dose.

For persons over 18 in the US population who may be at risk of occupational exposure to the Zaire ebolavirus, the Advisory Committee on Immunization Practices (ACIP) advised pre-exposure prophylactic immunization with rVSV-ZEBOV on February 26, 2020.

In 2019, during an Ebola outbreak in the Democratic Republic of the Congo, a two-dose vaccination regimen of a separate vaccine that was also intended to protect the Zaire ebolavirus species of Ebola was used as part of a research protocol. Ad26.ZEBOV and MVA-BN-Filo are two separate vaccine components used in the two doses of this regimen, which calls for an initial dosage and a “booster” injection 56 days later. The FDA has not yet approved for routine use of this vaccination.

Be Cautious

The following signs and symptoms should be taken seriously: red eyes, vomiting, diarrhea, abdominal pain, headache, sore throat, a rash that resembles measles, and bleeding from bodily openings.

In a statement released yesterday, the World Health Organization (WHO) mentioned that the Uganda Virus Research Institute (UVRI) verified the case after analyzing samples from the deceased, who had been treated for malaria initially before being found to have Ebola.

Gloria Flynt

I am a Research Content Specialist in I have been working with for over 6 months. is a digital platform that provides news and analysis on business, economy, technology and entrepreneurship in worldwide. I love reading and writing about anything that has to do with science, technology, and developments in the digital world.

Related Articles

Back to top button